Search
for
Sort by
Research 601–630 of 1000+
- Signs of some hematological diseases with the help of monoclonal antibodies LT-1, LT-2, LT-7
- Culprits of Medication-Induced Telogen Effluvium, Part 2
- Iatrogenic Cushing’s syndrome post intralesional triamcinolone acetonide in Oral submucous fibrosis: 2 case reports
- ASPECTOS DA SUPLEMENTAÇÃO COM CREATINA NO TRATAMENTO DE PACIENTES COM DIABETES MELLITUS TIPO 2
- Referee report. For: Autologous stromal vascular fraction cells combined with platelet-rich plasma for androgenic alopecia treatment: a case series [version 1; peer review: 2 approved with reservations]
- Structural basis for the catalysis and inhibition of human steroid 5α‐reductase 2
- Referee report. For: Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study [version 1; referees: 2 approved]
- Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
- Diagnosis by Hair Sample:A Rare Case of Netherton Syndrome in a 2-Year-Old Girl
- Modulation of sonic hedgehog, patched and patched-2 expression by epidermal growth factor signaling in mouse hair follicle formation
- Autologous Platelet-Rich Plasma (PRP) for Treating Androgenetic Alopecia: A Novel Treatment Protocol Standardized on 2 Cases
- Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials
- Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF‐κB‐ and MAPK‐ERK1/2‐mediated COX‐2 expression
- Effects of two estroprogestins containing ethynilestradiol 30mug and drospirenone 3 mg and ethynilestradiol 30mug and chlormadinone 2 mg on skin and hormonal hyperandrogenic manifestations
- Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase
- Menopause, skin and common dermatoses. Part 2: skin disorders
- Cloning, expression and characterization of rhesus macaque types 1 and 2 5alpha-Reductase: evidence for mechanism-Based inhibition by finasteride
- An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical Liquid 0.2% versus Minoxidil 5% Solution in Male Androgenetic Alopecia
- Dermatologic care of sexual and gender minority/LGBTQIA youth, Part 2: Recognition and management of the unique dermatologic needs of SGM adolescents
- FUT vs. FUE Graft Survival: A Side-by-Side Study of 3 Patients Undergoing a Routine 2,000+ Graft Hair Transplantation
- New effects of caffeine on corticotropin‐releasing hormone (CRH)‐induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH‐R1/2, IP<sub>3</sub>‐R, ACTH, MC‐R2) and the neurogenic non‐HPA axis (substance P, p75<sup>NTR</sup>and TrkA) in<i>ex vivo</i>human male androgenetic scalp hair follicles
- Immunofluorescence Tomography: High-resolution 3-D reconstruction by serial-sectioning of methacrylate embedded tissues and alignment of 2-D immunofluorescence images
- A novel point mutation of keratin 17 (<i>KRT17</i>) in a Japanese family with pachyonychia congenita type 2: an RNA-based genetic analysis using a single hair bulb
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
- Dermatology, ed. 2
- In silico screening of Moroccan medicinal plants with the ability to directly inhibit the novel coronavirus, SARS-CoV-2
- A Powerful Method for Pleiotropic Analysis under Composite Null Hypothesis Identifies Novel Shared Loci Between Type 2 Diabetes and Prostate Cancer
- Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas
- Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus